World’s First Gene Therapy Allows Deaf Toddler to Hear

Results from the Opal trial have shown promising results, with the potential for a cure for deafness being discussed. The trial, which has shown almost normal hearing restoration, has been particularly successful in terms of hearing soft sounds. While it is unknown whether the participants can understand speech in the same way as normal, they have been able to respond to soft sounds effectively.

Another child has also received gene therapy treatment at Cambridge University Hospitals, showing positive results just six weeks after surgery. Trials for gene therapies for deafness are also taking place in China and the US. It is estimated that there are approximately 20,000 individuals in several countries with auditory neuropathy due to OTOF mutations. This trial will provide valuable information on the effectiveness of gene therapy for deafness caused by specific genetic factors.

Martin McLean, a senior policy adviser at the National Deaf Children’s Society, emphasized that with the right support, deafness should never be a barrier to happiness or fulfillment. This sentiment was echoed by Mrs. Sandy, who shared that her daughters Opal and Nora enjoy making noise and playing together. Opal has started to talk and enjoys playing musical instruments, while Nora likes reading to her and dancing with her in the kitchen.

The results of the Chord trial were presented at the American Society of Gene and Cell Therapy conference in Baltimore. The promising outcomes from the trial suggest that gene therapy could potentially revolutionize the treatment of deafness caused by genetic mutations. With ongoing research and advancements in gene therapy, there is hope for a future where deafness can be effectively treated and cured.